Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroids and/or IVIG for Fulminant Myocarditis
NCT06896253Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
01
Overview
A Phase 2 trial of methylprednisolone, immune globulin in Fulminant myocarditis (FM), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
methylprednisoloneimmune globulin
03
Conditions
Fulminant myocarditis (FM)
Beyond the preview
Go deeper on NCT06896253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896253.